Latest news with #GoodManufacturingPractice
Time Business News
3 days ago
- Business
- Time Business News
GMP Certification Services for Tenders in Qatar
In Qatar's tightly regulated pharmaceutical, food, and healthcare industries, obtaining GMP (Good Manufacturing Practice) certification has become a strategic necessity—especially for businesses looking to secure government contracts. Whether supplying medicines to Hamad Medical Corporation, manufacturing packaged foods for schools, or producing cosmetics for hospital use, GMP compliance proves your company's dedication to safety, quality, and international best practices. Government institutions in Qatar—including those under the Ministry of Public Health (MoPH)—require that suppliers meet international safety and quality standards. GMP certification ensures that your production environment: Maintains hygienic facilities Follows documented procedures Ensures employee competence and training Tracks product batches for recall readiness Implements continuous quality control systems This reduces risk for public agencies and aligns with the Qatar National Vision 2030 commitment to high health and safety standards. GMP supports Qatar's broader goals for consumer protection, public health, and economic diversification. Companies that implement GMP are better equipped to meet regulations enforced by MoPH and international partners. This is especially critical in sectors supplying: Public healthcare and hospitals Government-run food programs Military and municipal supply chains By aligning with GMP standards, your business becomes a preferred vendor in Qatar's growing public sector. Pharmaceuticals – To qualify for MoPH registration and government tenders – To qualify for MoPH registration and government tenders Food and Beverage Manufacturing – Especially for institutional or export markets – Especially for institutional or export markets Cosmetics & Personal Care – For supplies to hotels, hospitals, and wellness centers – For supplies to hotels, hospitals, and wellness centers Medical Devices & Supplements – Subject to increased scrutiny under health regulations Improves Evaluation Scores – Many RFQs assign points to quality compliance and safety systems. Demonstrates Operational Maturity – GMP shows your business has predictable, traceable processes. Accelerates Government Approvals – Certified businesses face fewer technical clarifications. Builds Procurement Trust – Officials prefer working with vendors that proactively manage risk. To become GMP certified, companies typically follow these five stages: Gap Analysis – Evaluate compliance with GMP standards System Development – Create or update SOPs, sanitation procedures, and documentation Employee Training – Educate teams on hygiene, safety, and process control Internal Audit – Conduct a mock audit to identify areas of improvement Third-Party Certification – Undergo assessment by an accredited GMP certification body Working with a Qatar-based GMP consultancy ensures that documentation and practices meet local and international requirements, accelerating approval. Government procurement in Qatar emphasizes reliability, hygiene, and international standardization. GMP-certified companies are: Seen as low-risk, high-trust suppliers More likely to meet regulatory benchmarks Positioned to win tenders in healthcare, food, and industrial supply chains Aligned with sustainability and transparency goals of Vision 2030 In Qatar's public procurement system, GMP is no longer optional—it's a key to eligibility and long-term success. From compliance to competitiveness, GMP gives your company the edge it needs to secure government tenders and operate at global standards. Whether you're a food processor, pharmaceutical company, or cosmetic product manufacturer, GMP certification positions your business as a trusted partner for national development goals. If you're preparing to pursue tenders, we recommend exploring reliable GMP certification services in Qatar that offer local expertise, regulatory alignment, and full support from documentation to audit. Partnering with an experienced team can significantly streamline your certification journey and boost your tender success rate. TIME BUSINESS NEWS
Business Upturn
4 days ago
- Business
- Business Upturn
Dr. Reddy's receives 7 observations from USFDA after inspection at Srikakulam plant
By Aditya Bhagchandani Published on July 18, 2025, 18:21 IST Dr. Reddy's Laboratories Ltd. announced on July 18 that the United States Food & Drug Administration (USFDA) has completed a Good Manufacturing Practice (GMP) and Pre-Approval Inspection (PAI) at its formulations manufacturing facility FTO 11, located in Srikakulam, Andhra Pradesh. According to the company's filing with stock exchanges, the inspection was conducted over eight days, from July 10 to July 18, 2025. At the conclusion of the inspection, the USFDA issued a Form 483 with seven observations. Dr. Reddy's stated that it would address the observations within the stipulated timeline, as per regulatory requirements. The company said the disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and is meant for public record and investor information. The Hyderabad-headquartered pharmaceutical major operates several manufacturing facilities in India and abroad, and this development comes as part of its routine regulatory inspections for ongoing compliance and product approvals. Disclaimer: This information is based solely on the company's official disclosure dated July 18, 2025. Business Upturn or the author is not liable for any actions taken based on this information. Investors are advised to independently verify and consult financial advisors before making investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
4 days ago
- Business
- Business Upturn
Concord Biotech completes EU GMP inspection at Dholka API facility
By Aditya Bhagchandani Published on July 18, 2025, 13:10 IST Shares of Concord Biotech may remain in focus after the company announced that it has successfully completed the European Union Good Manufacturing Practice (EU GMP) inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility in Dholka, Gujarat. In a regulatory filing on July 18, 2025, the company informed the exchanges that the inspection at the Dholka facility was conducted from July 14 to July 18, 2025. The audit was concluded without any critical observations, reflecting the company's adherence to global regulatory standards. 'This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance across all aspects of our operations. It reflects our dedication to excellence and our continued focus on meeting the rigorous requirements of global regulatory authorities,' the company said in the statement. The EU GMP certification is considered a key milestone for pharmaceutical companies, enabling them to export APIs to regulated markets in Europe and beyond. Hina Patel, Company Secretary and Compliance Officer of Concord Biotech, signed off the communication, which was addressed to both the National Stock Exchange of India and the BSE Limited. Investors and market participants will watch the stock closely as the EU GMP certification strengthens Concord Biotech's position in international markets and reinforces confidence in its manufacturing quality. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
L'Orient-Le Jour
4 days ago
- Health
- L'Orient-Le Jour
Pharma M denies Probiolife safety allegations
Nearly two weeks after a televised investigation raised concerns about alleged unsafe manufacturing practices at the facility producing Probiolife, local supplement maker Pharma M S.A.L. has issued a statement rejecting the claims targeting the company as 'defamatory' and 'misleading.' The company's response, published Thursday, accuses unnamed competitors of orchestrating a media campaign to damage its reputation and warns of legal action against those spreading what it calls false information. In the televised investigative report earlier in July ignited controversy over the safety and quality standards of pharmaceutical and supplement manufacturing in the country, prompting a response from the Syndicate of Pharmaceutical Manufacturers in Lebanon (SPIL) the next day, which stated that it supported investigations into any possible violations. It spotlighted troubling conditions at a Lebanese factory producing Probiolife, a probiotic supplement marketed for digestive issues such as IBS, diarrhea and gut inflammation. The report alleged that the product is being packaged in "unsanitary, primitive conditions," lacking proper stabilizers, sterilization procedures or regular oversight from the Public Health Ministry. Company subject to 'regular inspections' Pharma M stated in its announcement on Thursday that "the company affirms its full commitment to complying with all applicable laws and regulations, especially those issued by the Lebanese Public Health Ministry and other relevant regulatory bodies, with respect to the manufacturing and packaging of nutritional and health supplements." Pharma M also insisted that the company is regularly and systematically "subject to inspection and oversight, and it fully adheres to all approved health and technical standards, including quality assurance, general hygiene and the safety of raw materials used." Although Probiolife is officially registered with the Sanitary Engineering Department and is currently being tested in a clinical trial for gastroesophageal reflux (GERD), lab results and footage presented suggested that consumers may be unknowingly exposed to mislabeled or contaminated doses, an accusation that Pharma M categorically denied. 'Products are safe, effective and fully compliant' The Syndicate of Pharmaceutical Manufacturers in Lebanon (SPIL) stated that it supported investigations into any possible violations. The syndicate also emphasized that Lebanese pharmaceutical factories 'operate according to the highest internationally recognized Good Manufacturing Practice [GMP] standards and are periodically subject to oversight by the competent authorities, both locally and internationally.' While affirming its respect for media scrutiny, SPIL called on journalists to consult with relevant authorities before implicating the pharmaceutical sector as a whole. 'We hope that all media outlets will communicate with the relevant authorities ... to obtain clarification before discussing the pharmaceutical industry as a whole in news reports and casting doubt on the quality of the sector's activity,' the statement read. Pharma M assured its consumers "that all of its products are safe, effective and fully compliant with all applicable standards and specifications. All raw materials used in production are exclusively imported from leading global manufacturers who hold internationally recognized certifications. The company urges the public to remain cautious and avoid falling prey to malicious rumors that lack any reliable scientific evidence. Pharma M also reaffirms its full openness and willingness to cooperate with any transparent investigation conducted under the supervision of competent official and judicial authorities."
United News of India
4 days ago
- Business
- United News of India
Lupin gets GMP from TGA Australia for Dabhasa API facility, Gujarat
Hyderabad, July 17 (UNI) Global pharma major Lupin Limited (Lupin) today announced that the API manufacturing facility of its wholly owned subsidiary, Lupin Manufacturing Solutions (LMS), in Dabhasa, Gujarat, has received the Good Manufacturing Practice (GMP) certification from the Therapeutic Goods Administration (TGA), Australia's medicines and medical devices regulator. LMS offers pharmaceutical CDMO services and is engaged in the manufacturing and supply of APIs. 'We are pleased to have received the GMP certification from TGA for our Dabhasa facility, This reflects the high standard of our manufacturing practices and expertise of our team at Dabhasa,' Dr. Abdelaziz Toumi, Chief Executive Officer, Lupin Manufacturing Solutions said in a release. 'As we continue to expand our global footprint, we remain focused on quality, compliance, and the highest standards of operational integrity, setting new benchmarks in the CDMO space,' Dr Toumi added. UNI KNR BM
